Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
IFM2017-03 trial of Revlimid/Darzalex with 2 cycles of dex versus triplet with continuous dex finds DRAMATICALLY reduced progression risk (53.4 mos (95% CI 35.3-not reached) vs. 22.5 mos (HR 0.51, 95% CI 0.37-0.70, p<0.0001)).”
Title: Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Authors: Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Borhane Slama, Lionel Karlin, Frédéric Orsini Piocelle, Mamoun Dib, Laurence Sanhes, Pierre Morel, Abderazzak El Yamani, Mourad Tiab, Reza Tabrizi, Valentine Richez, Laurent Garderet, Bruno Royer, Benoit Bareau, Clara Mariette, Emmanuel Fleck, Daniela Robu, Claire Calmettes, Sophie Rigaudeau, Hélène Demarquette, Laurent Frenzel, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf, Noémie Bigot, Aurore Perrot, Jill Corre, Jean-Yves Mary, Hervé Avet-Loiseau, Philippe Moreau, Xavier Leleu, and Thierry Facon
You can read the Full Article in The Lancet.
You can find more posts featuring Robert Orlowski on OncoDaily.
